LAM-181 is under clinical development by Laminar Pharmaceuticals and currently in Phase II for Neuropathic Pain (Neuralgia). According to GlobalData, Phase II drugs for Neuropathic Pain (Neuralgia) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LAM-181’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LAM-181 overview
Laminar Pharmaceuticals overview
Laminar Pharmaceuticals (Laminar Pharmaceutical) is a biopharmaceutical company that includes in drug discovery, design and development of molecules based on a novel therapeutic such as membrane lipid therapy (MLT) or melitherapy. The company’s product pipeline includes synthetic fatty acid molecules which target the cell membrane to modulate precise signaling. Its pipeline products includes LAM561 for glioma in adults and children, LPI09C2-5/11 treats cancer, LAM226 which treats neurodegeneration, LAM181 for neuropathic pain, LAM182 targets oncology and LAM561 which treats glioma pediatric; LAMAC1/2 for antiinfective. The company’s therapeutic areas are glioblastoma, aggressive cancers, neurodegenerative, metabolic and inflammatory diseases. Laminar Pharmaceutical is headquartered in Palma, Spain.
For a complete picture of LAM-181’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
